3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Tissue Regenix Group's 3-Year ROIIC % for the quarter that ended in Dec. 2024 was 59.52%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Tissue Regenix Group's 3-Year ROIIC % or its related term are showing as below:
FRA:LSW's 3-Year ROIIC % is not ranked
in the Biotechnology industry.
Industry Median: -4.42
vs FRA:LSW: 59.52
Tissue Regenix Group (FRA:LSW) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Tissue Regenix Group 3-Year ROIIC % Related Terms
Tissue Regenix Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Tissue Regenix Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's 3-Year ROIIC % falls into.
Tissue Regenix Group's 3-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 0.452 (Dec. 2024) - -3.45142 (Dec. 2021) )
/
( 38.32 (Dec. 2024) - 31.762 (Dec. 2021) )
=
3.90342
/
6.558
=
59.52%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Tissue Regenix Group (FRA:LSW) has a 3-Year ROIIC % of 59.52 as of Dec. 2024. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tissue Regenix Group and its competitors. This is 54% above median its historical median of 38.59.
Is Tissue Regenix Group's 3-Year ROIIC % too high?
Tissue Regenix Group's current 3-Year ROIIC % of 59.52 is 54% above median its 10-year median of 38.59. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's 3-Year ROIIC % compare to VRTX and REGN?
Tissue Regenix Group's 3-Year ROIIC % of 59.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Tissue Regenix Group and its competitors. Tissue Regenix Group's current 3-Year ROIIC % is 59.52, which is 54% above median its own 10-year median of 38.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current 3-Year ROIIC % of 59.52. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current 3-Year ROIIC % is 59.52, which is 54% above median its 10-year median of 38.59. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current 3-Year ROIIC % is 59.52 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
3-Year ROIIC %: 59.52 (54% above median its 10-year median of 38.59)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
